Join Growin Stock Community!

昱展新藥6785.TW Overview

TW StockBiotech. & Medical
(No presentation for 6785)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

昱展新藥（6785）Overall Performance

昱展新藥（6785）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

昱展新藥（6785） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

昱展新藥（6785）Key Information

昱展新藥（6785）Profile

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

昱展新藥（6785）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
72.07%
Net Margin
-2342.78%
Revenue Growth (YoY)
-99.74%
Profit Growth (YoY)
-99.81%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
72.07%
Net Margin
-2342.78%
Revenue Growth (YoY)
-99.74%
Profit Growth (YoY)
-99.81%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
default symbol

6785

昱展新藥

185.50D

-7.01%

(-0.07)

  • When is 6785's latest earnings report released?

    The most recent financial report for 昱展新藥 (6785) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6785's short-term business performance and financial health. For the latest updates on 6785's earnings releases, visit this page regularly.

  • How is 6785's revenue growth?

    In the latest financial report, 昱展新藥 (6785) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6785 have?

    At the end of the period, 昱展新藥 (6785) held Total Cash and Cash Equivalents of 1.84B, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6785's EPS continuing to grow?

    According to the past four quarterly reports, 昱展新藥 (6785)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6785?

    昱展新藥 (6785)'s Free Cash Flow (FCF) for the period is 4.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 219.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.